



## Lydisilka

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
II/0026	Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update information on paediatric population based on results from study MIT-Es001-C303. This is a phase 3, open-label, single-arm study to evaluate the safety, compliance and pharmacokinetics associated with the use of a combined oral	30/01/2025	26/02/2025	SmPC and PL	In a phase 3 study including adolescents aged 12 to-17 years, the product was well-tolerated and no safety concerns were raised during the study. The contraceptive efficacy is expected to be the same in post-menarchal adolescents compared to users 18 years and older. There is no relevant use of Drovelis in pre-

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>contraceptive containing 15 mg estetrol monohydrate and 3 mg drospirenone in post-menarchal female adolescents for 6 cycles. The Package Leaflet is updated accordingly.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				<p>menarcheal adolescents. For more information, please refer to the Summary of Product Characteristics.</p>
II/0025	<p>Update of sections 4.2 and 5.2 of the SmPC in order to update information regarding renal impairment based on final results from study MIT-Do001-C103. This is a Phase 1, open-label, sequential group, single-dose study to evaluate the pharmacokinetics and safety of estetrol monohydrate (E4) in female subjects with varying degrees of renal function. The Package Leaflet is updated accordingly.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	12/12/2024	26/02/2025	SmPC and PL	
IA/0027/G	<p>This was an application for a group of variations.</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>	28/06/2024	n/a		

PSUSA/10938 /202311	Periodic Safety Update EU Single assessment - drospirenone / estetrol	13/06/2024	n/a		PRAC Recommendation - maintenance
II/0021	Update of sections 4.2 and 5.2 of the SmPC in order to update information regarding hepatic impairment based on final results from study MIT-Do001-C102; this is a Phase 1, open-label, parallel group, single-dose study to evaluate the pharmacokinetics and safety of estetrol (E4) in subjects with varying degrees of hepatic function.  C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	11/04/2024	26/02/2025	SmPC	For more information, please refer to the Summary of Product Characteristics.
IB/0023	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	07/02/2024	n/a		
IA/0022/G	This was an application for a group of variations.  A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites	07/12/2023	25/04/2024	Annex II and PL	
PSUSA/10938 /202305	Periodic Safety Update EU Single assessment - drospirenone / estetrol	30/11/2023	n/a		PRAC Recommendation - maintenance

PSUSA/10938 /202211	Periodic Safety Update EU Single assessment - drospirenone / estetrol	08/06/2023	n/a		PRAC Recommendation - maintenance
IB/0018	C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	30/03/2023	25/04/2024	SmPC and PL	
IAIN/0019	B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	21/03/2023	n/a		
IB/0016	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	03/03/2023	n/a		
PSUSA/10938 /202205	Periodic Safety Update EU Single assessment - drospirenone / estetrol	01/12/2022	n/a		PRAC Recommendation - maintenance
IA/0015/G	This was an application for a group of variations.  B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	30/11/2022	n/a		
IB/0014	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale	29/11/2022	n/a		

	(supported by real time data)				
IB/0012	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	15/11/2022	n/a		
IB/0011/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved</p>	15/11/2022	n/a		

	<p>manufacturer</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation</p>				
IAIN/0013/G	<p>This was an application for a group of variations.</p> <p>B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>	18/10/2022	n/a		
IA/0009/G	<p>This was an application for a group of variations.</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor</p>	25/07/2022	n/a		

	<p>changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>				
PSUSA/10938 /202111	Periodic Safety Update EU Single assessment - drospirenone / estetrol	10/06/2022	n/a		PRAC Recommendation - maintenance
IB/0008	C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	22/04/2022	29/09/2022	SmPC and PL	Update of Sections 4.4, 4.5 and 4.8 of the SmPC with wording based on PRAC recommendation formulated for PSUSA (PSUSA/00002182/202101) on nomegestrol/estradiol (CMDh meeting held on 12-14 October 2021). The PL was updated accordingly.
II/0006/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation</p>	31/03/2022	29/09/2022	Annex II and PL	
II/0004/G	This was an application for a group of variations.	16/12/2021	n/a		

B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)

B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)

B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)

B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation

B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)

B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation

B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation

B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation

B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter

B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method

B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a

	<p>non-significant specification parameter</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation</p> <p>B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>				
II/0001/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF</p>	09/12/2021	n/a		
IAIN/0005	<p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p>	16/11/2021	n/a		

II/0003	B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF	11/11/2021	n/a		
II/0002	<p>Update of section 5.3 of the SmPC following a revision of the Environmental Risk Assessment (ERA) in order to include the E4 PECsw based on a refined Fpen of 0.0044. In addition, the MAH has taken the opportunity to implement minor editorial changes in the SmPC, the Labelling and Package Leaflet.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	30/09/2021	29/09/2022	SmPC and PL	